The Asia Pacific AI In Cancer Diagnostics Market would witness market growth of 29.6% CAGR during the forecast period (2022-2028).
Diagnosis of cancer starts with a complete body examination along with an entire medical report of the patient. As cancer is being detected, imaging procedures such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, fiber-optic endoscopy, and X-ray assist doctors to find the cancer location and size of the tumor.
In most cases to detect cancer, biopsy treatment is tested in humans in which a tissue specimen is detached from the diagnosis tumor and researched within a microscope to identify cancer cells in the body. As the testing of cancer comes out as positive, other tests are performed to deliver accurate cancer information. The following process is termed the staging where all the crucial information such as the spread of cancer in the body is acknowledged.
For example, a group of various researchers developed a methylation-based classifier that was originally designed to categorize subtypes of medulloblastomas. Later on, the project was expanded by the German-led team to include more than 100 extra cancers of the central nervous system. After the result of the reports were announced in March 2018, afterward, scientists introduced classifiers for the entire marketplace.
Head and neck cancer are the third most common cancer in India with about 52 067 mortalities and 77 000 diagnoses in 2012. Moreover, in China, caretaking of the cancer patient with non-disclosure of diagnosis to the patients is one of the most serious problems. As per the Law of the People’s Republic of China Medical professionals, or practitioners should open up with the truth to the patients and their caretakers. The law forces a legal authority on a medical specialist for a negative effect on the patient due to the resulting disclosure of diagnosis.
The China market dominated the Asia Pacific AI In Cancer Diagnostics Market by Country in 2021; thereby, achieving a market value of $36 million by 2028. The Japan market is registering CAGR of 28.8% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 30.4% during (2022 - 2028).
Based on End-user, the market is segmented into Hospital, Surgical Centers & Medical Institutes and Others. Based on Component, the market is segmented into Software Solutions, Hardware and Services. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Brain Tumor, Skin Cancer & Cervical Cancer, Prostate & Colorectal Cancer and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide AI In Cancer Diagnostics Market is Projected to reach USD 509 Million by 2028, at a CAGR of 28.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Microsoft Corporation, Flatiron Health, Paige AI, Inc., PathAI, Inc., Therapixel, Tempus, Inc., SkinVision BV, Cancer Center Sp. z o.o., Medial EarlySign and Kheiron Medical Technologies Limited.
By End-user
By Component
By Cancer Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 